Your browser doesn't support javascript.
loading
A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC.
Lisberg, A; Cummings, A; Goldman, J W; Bornazyan, K; Reese, N; Wang, T; Coluzzi, P; Ledezma, B; Mendenhall, M; Hunt, J; Wolf, B; Jones, B; Madrigal, J; Horton, J; Spiegel, M; Carroll, J; Gukasyan, J; Williams, T; Sauer, L; Wells, C; Hardy, A; Linares, P; Lim, C; Ma, L; Adame, C; Garon, Edward B.
Afiliación
  • Lisberg A; David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, California.
  • Cummings A; David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, California.
  • Goldman JW; David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, California.
  • Bornazyan K; David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, California.
  • Reese N; David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, California.
  • Wang T; David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, California.
  • Coluzzi P; David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, California.
  • Ledezma B; David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, California.
  • Mendenhall M; David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, California.
  • Hunt J; David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, California.
  • Wolf B; David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, California.
  • Jones B; David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, California.
  • Madrigal J; David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, California.
  • Horton J; David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, California.
  • Spiegel M; David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, California.
  • Carroll J; David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, California.
  • Gukasyan J; David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, California.
  • Williams T; David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, California.
  • Sauer L; David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, California.
  • Wells C; David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, California.
  • Hardy A; David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, California.
  • Linares P; David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, California.
  • Lim C; David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, California.
  • Ma L; David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, California.
  • Adame C; David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, California.
  • Garon EB; David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, California. Electronic address: egaron@mednet.ucla.edu.
J Thorac Oncol ; 13(8): 1138-1145, 2018 08.
Article en En | MEDLINE | ID: mdl-29874546
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Anticuerpos Monoclonales Humanizados / Antígeno B7-H1 / Neoplasias Pulmonares Tipo de estudio: Prognostic_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Año: 2018 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Anticuerpos Monoclonales Humanizados / Antígeno B7-H1 / Neoplasias Pulmonares Tipo de estudio: Prognostic_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Año: 2018 Tipo del documento: Article